Sitagliptin
Back to searchMolecule Structure
Scientific Name
Sitagliptin
Description of the Drug
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used for the management of type 2 diabetes mellitus.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB01261
http://www.drugbank.ca/drugs/DB01261
Brand Name(s)
Januvia
Company Owner(s)
Merck Sharp And Dohme Llc A Sub Of Merck And Co Inc, Merck Sharp And Dohme Corp
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Dipeptidyl peptidase IV | SINGLE PROTEIN | INHIBITOR | CHEMBL284 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL17783 | |||
PharmGKB | PA164748978 | |||
Human Metabolome Database | HMDB0015390 | |||
DrugBank | DB01261 | |||
PubChem: Thomson Pharma | 14904024 | 16466401 | ||
PubChem | 4369359 | |||
Mcule | MCULE-2101761133 | |||
LINCS | LSM-5363 | |||
Nikkaji | J2.231.708C | |||
PDBe | 715 | |||
BindingDB | 11162 | |||
EPA CompTox Dashboard | DTXSID70197572 | |||
DrugCentral | 2448 | |||
Brenda | 27125 | 151478 | 14136 | 39010 |
ChemicalBook | CB01449778 | |||
Guide to Pharmacology | 6286 | |||
rxnorm | SITAGLIPTIN PHOSPHATE | JANUVIA | SITAGLIPTIN | |
ChEBI | 40237 | |||
ZINC | ZINC000001489478 |